Aprea Therapeutics, Inc. Common stock (APRE) Stock Price

APREStock

$0.84−47.09%52W

Market Cap$10.56M

P/E—

PEG Ratio—

Div yield—

Beta-1.23

APRE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.09%

Price vs S&P 500 (4W)38.76%

VGM Score26.06

Book Value / Share (Quarterly)$3.53

P/TBV (Annual)0.54x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-1.00

Price vs S&P 500 (YTD)-14.51%

Net Profit Margin (TTM)-4409.14%

EPS (TTM)$-1.54

10-Day Avg Trading Volume0.95M

EPS Excl Extra (TTM)$-1.54

EPS (Annual)$-1.93

ROI (Annual)-95.68%

Cash / Share (Quarterly)$3.88

Revenue Growth QoQ (YoY)-98.38%

ROA (Last FY)-79.08%

Revenue Growth TTM (YoY)-90.40%

EBITD / Share (TTM)$-1.44

ROE (5Y Avg)-145.80%

Operating Margin (TTM)-4631.10%

Cash Flow / Share (Annual)$-1.57

P/B Ratio0.19x

P/B Ratio (Quarterly)0.21x

Net Income / Employee (Annual)$-1,574,900

EV / Revenue (TTM)-133.92x

Net Interest Coverage (TTM)-78.82x

ROA (TTM)-50.24%

EPS Incl Extra (Annual)$-1.93

Current Ratio (Annual)5.63x

Quick Ratio (Quarterly)8.77x

3-Month Avg Trading Volume0.21M

52-Week Price Return-47.09%

Revenue / Employee (TTM)$15,400

Tangible BV / Share (Quarterly)$5.78

P/S Ratio (Annual)28.69x

Asset Turnover (Annual)0.02x

52-Week High$1.69

EPS Excl Extra (Annual)$-1.93

CapEx CAGR (5Y)-12.39%

Tangible BV CAGR (5Y)5.67%

26-Week Price Return4.84%

Quick Ratio (Annual)5.28x

13-Week Price Return-9.88%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.92x

Enterprise Value$-38.27M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-53.04%

Revenue / Employee (Annual)$35,700

Pretax Margin (Annual)-4409.14%

Cash / Share (Annual)$1.78

3-Month Return Std Dev89.11%

Net Income / Employee (TTM)$-1,494,400

ROE (Last FY)-95.68%

Net Interest Coverage (Annual)-23.37x

EPS Basic Excl Extra (Annual)$-1.93

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.54

ROI (TTM)-58.84%

P/S Ratio (TTM)28.69x

Revenue / Share (Annual)$0.04

Tangible BV / Share (Annual)$10.15

Price vs S&P 500 (52W)-65.65%

Year-to-Date Return-1.69%

5-Day Price Return4.15%

EPS Normalized (Annual)$-1.93

ROA (5Y Avg)-126.92%

Net Profit Margin (Annual)-4409.14%

Month-to-Date Return35.26%

Cash Flow / Share (TTM)$-3.97

EBITD / Share (Annual)$-2.02

Operating Margin (Annual)-4631.10%

ROI (5Y Avg)-145.80%

EPS Basic Excl Extra (TTM)$-1.54

P/TBV (Quarterly)0.67x

P/B Ratio (Annual)0.45x

Pretax Margin (TTM)-4409.14%

Book Value / Share (Annual)$1.61

Price vs S&P 500 (13W)-11.83%

Beta-1.23x

Revenue / Share (TTM)$0.01

ROE (TTM)-58.84%

52-Week Low$0.55

gGradeF

mGradeC

vgmGradeD

APRE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.23	-$0.07	+69.12%(+$0.16)
Q1 2026	May 13, 2026	-$0.23	-$0.22	+4.35%(+$0.01)
Q4 2025	Mar 16, 2026	-$0.36	-$0.32	+11.11%(+$0.04)
Q3 2025	Nov 12, 2025	-$0.10	-$0.47	-370.00%(-$0.37)
Q2 2025	Aug 12, 2025	-$0.71	-$0.53	+25.35%(+$0.18)

APRE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

4.30

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
APREAprea Therapeutics, Inc. Common stock	—	F	C	$0.84
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Aprea Therapeutics, Inc. Common stock

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology therapies based on synthetic lethality. Its lead program, ATRN-119, is a small-molecule ATR inhibitor in clinical development for solid tumors. The company is also advancing APR-1051, an oral WEE1 inhibitor that recently entered clinical trials.